Testing Experimental Schizophrenia Medication
common.study.values.description
“Study of CAD-9303 in Subjects With Schizophrenia”
This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized, double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


Drug - CAD-9303
Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
Drug - Placebos
Capsules
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers
common.study.values.clinical-trial-id
NCT04306146
participant.views.study.view.id
aQWVMd